Oppenheimer analyst Rohit Vanjani came out today with a neutral stance on shares of Opko Health Inc. (NASDAQ:OPK), after the drug maker reported second-quarter results, posting revenue …
Rohit Vanjani of Oppenheimer rates stocks in the biotechnology sector and is one of the top 25 analysts rated on TipRanks. Yesterday, Vanjani made …
Openheimer analyst Rohit Vanjani is weighing in on Opko Health Inc. (NYSE:OPK), after the company released its first-quarter results, posting revenue of $30.
In a research report issued today, Oppenheimer analyst Rohit Vanjani maintained an Outperform rating on OvaScience Inc (NASDAQ:OVAS) with a price target of …
In a research report issued today, Oppenheimer analyst Rohit Vanjani maintained an Outperform rating on OvaScience Inc (NASDAQ:OVAS) with a $60 price target, after hosting investor …
In a research report released Tuesday, Oppenheimer analyst Rohit Vanjani reiterated a Perform rating on Opko Health Inc. (NYSE:OPK), as shares have traded up nearly 45% …
Oppenheimer healthcare analyst Rohit Vanjani weighed in today with his thoughts on NPS Pharma (NASDAQ:NPSP), after the company and Shire (NASDAQ:SHPG) announced a definitive merger agreement whereby …
In a research report sent to investors today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $58 price …
Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of $40, which represents a potential upside …
Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a price target of $12, which represents a potential upside …
